Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02362035
Title ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Research Site Tucson Arizona 85704 United States Details
Research Site Los Angeles California 90095 United States Details
Research Site Denver Colorado 80218 United States Details
Research Site Washington District of Columbia 20007 United States Details
Research Site Niles Illinois 60714 United States Details
Research Site Boston Massachusetts 2215 United States Details
Research Site Rochester Minnesota 55905-0001 United States Details
Research Site Omaha Nebraska 68198-7680 United States Details
Research Site Columbus Ohio 43210 United States Details
Research Site Greenville South Carolina 29605 United States Details
Research Site Nashville Tennessee 37203 United States Details
Research Site Dallas Texas 75246 United States Details
Research Site Houston Texas 77030 United States Details
Research Site San Antonio Texas 78217 United States Details
Research Site Tyler Texas 75702 United States Details
Research Site Fairfax Virginia 22031 United States Details
Research Site Roanoke Virginia 24014 United States Details
Research Site Vancouver Washington 98684 United States Details
Research Site Yakima Washington 98902 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field